U.S. Preventive Services Task Force banner
U.S. Preventive Services Task Force


Liquid-Based Cytology and Human Papillomavirus Testing to Screen for Cervical Cancer (continued)

References

1. International Agency for Research on Cancer. Cervix Cancer Screening. IARC Handbook of Cancer Prevention, vol. 10. Lyon, France: IARC Pr; 2005.

2. Arbyn M, Antilla A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. Luxembourg: Office for Official Publications of the European Communities; 2008.

3. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(Suppl 1):S1-15. [PMID: 16406226]

4. Center for Devices and Radiological Health. Approval Letter: Digene Hybrid Capture 2 High-Risk HPV DNA Test-P890064/S009. Rockville, MD: U.S. Food and Drug Administration; 2003. Accessed at www.accessdata.fda.gov/cdrh_docs/pdf/p890064s009a.pdf on 25 September 2011.

5. Center for Devices and Radiological Health. Summary of Safety and Effectiveness Data. Rockville, MD: U.S. Food and Drug Administration; 2002. Accessed at http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/recently-approveddevices/ucm082556.htm on 25 September 2011.

6. Arney A, Bennett KM. Molecular diagnostics of human papillomavirus. Lab Med. 2010;41:523-30.

7. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology. Obstet Gynecol. 2008;112:1419-44. [PMID: 19037054]

8. Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186-92. [PMID: 8463044]

9. Richart RM. Cervical intraepithelial neoplasia. Pathol Annu. 1973;8:301-28. [PMID: 4583016]

10. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907. [PMID: 17826171]

11. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis. 2007;11:223-39. [PMID: 17917567]

12. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9:425-34. [PMID: 18407790]

13. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346-55. [PMID: 17904957]

14. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol. 2009;114:1409-20. [PMID: 20134296]

15. Vesco KK, Whitlock EP, Eder M, Lin J, Burda BU, Senger CA, et al. Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Report No. 86. AHRQ Publication No. 11-05156-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2011.

16. Kulasingam S, Havrilesky L, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. AHRQ Publication No. 11-05157-EF-1. Rockville, MD: Agency for Heatlhcare Research and Quality; 2011.

17. Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, Lutz K. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review. Ann Intern Med. 2011;Oct 18. [Epub ahead of print]

18. Medical Services Advisory Committee. Liquid Based Cytology for Cervical Screening. MSAC Reference 12a. Canberra, Australia: Australia Department of Health and Aging; 2002.

19. Noorani HZ, Brown A, Skidmore B, Stuart GCE. Liquid-based cytology and human papillomavirus testing in cervical cancer screening. Technology Report no. 40. Ottawa: Canadian Coordinating Office of Health Technology Assessment; 2003.

20. Hartmann KE, Hall SA, Nanda K, Boggess JF, Zolnoun D. Screening for Cervical Cancer. Systematic Review No. 25. Rockville, MD: Agency for Healthcare Research and Quality; 2002.

21. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663-72. [PMID: 21684207]

22. Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev. 2011;20:1398-409. [PMID: 21602310]

23. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Schiffman M, et al. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. Obstet Gynecol. 2011;117:650-6. [PMID: 21343769]

24. Littell RD, Kinney W, Fetterman B, Cox JT, Shaber R, Poitras N, et al. Risk of cervical precancer and cancer in women aged 30 years and older with an HPV-negative low-grade squamous intraepithelial lesion screening result. J Low Genit Tract Dis. 2011;15:54-9. [PMID: 21192178]

25. Castle PE, Gutierrez EC, Leitch SV, Maus CE, McMillian RA, Nussbaumer WA, et al. Evaluation of a new DNA test for detection of carcinogenic human papillomavirus. J Clin Microbiol. 2011;49:3029-32. [PMID: 21632892]

26. Kotaniemi-Talonen L, Malila N, Anttila A, Nieminen P, Hakama M. Intensified screening among high risk women within the organised screening programme for cervical cancer in Finland. Acta Oncol. 2011;50:106-11. [PMID: 20560860]

27. Anttila A, Pokhrel A, Kotaniemi-Talonen L, Hakama M, Malila N, Nieminen P. Cervical cancer patterns with automation-assisted and conventional cytological screening: a randomized study. Int J Cancer. 2011;128:1204-12. [PMID: 20848590]

28. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011. [PMID: 21471563]

29. Franceschi S, Denny L, Irwin KL, Jeronimo J, Lopalco PL, Monsonego J, et al. Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer. 2011;128:2765-74. [PMID: 21207409]

30. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35. [PMID: 11306229]

31. National Institute for Health and Clinical Excellence. The Guidelines Manual. London: National Institute for Health and Clinical Excellence; 2006.

32. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25. [PMID: 14606960]

33. Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ. 2007;335:28. [PMID: 17517761]

34. Siebers AG, Klinkhamer PJ, Grefte JM, Massuger LF, Vedder JE, Beijers-Broos A, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009;302:1757-64. [PMID: 19861667]

35. Taylor S, Kuhn L, Dupree W, Denny L, De Souza M, Wright TC Jr. Direct comparison of liquid-based and conventional cytology in a South African screening trial. Int J Cancer. 2006;118:957-62. [PMID: 16152600]

36. Coste J, Cochand-Priollet B, de Cremoux P, Le Galès C, Cartier I, Molinié V, et al; French Society of Clinical Cytology Study Group. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ. 2003;326:733. [PMID: 12676841]

37. Hologic. ThinPrep Pap Test Quick Reference Guide: Endocervical Brush/Spatula Protocol. Marlborough, MA: Hologic; 2004. Accessed at www.thinprep.com/pdfs/pap_quick_reference.pdf on 25 September 2011.

38. TriPath Imaging. SurePath Technology is Changing Cervical Cancer Screening for the Better. Burlington, NC: TriPath Imaging; 2004. Accessed at www.nlma.nf.ca/documents/health_promotion/health_promotion_8.pdf on 25 September 2011.

39. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al; New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249-57. [PMID: 20089449]

40. Cárdenas-Turanzas M, Nogueras-Gonzalez GM, Scheurer ME, Adler-Storthz K, Benedet JL, Beck JR, et al. The performance of human papillomavirus high-risk DNA testing in the screening and diagnostic settings. Cancer Epidemiol Biomarkers Prev. 2008;17:2865-71. [PMID: 18843032]

41. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer. 2003;88:1570-7. [PMID: 12771924]

42. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-88. [PMID: 17942871]

43. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288:1749-57. [PMID: 12365959]

44. Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer. 2005;93:575-81. [PMID: 16136031]

45. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst. 2009;101:1612-23. [PMID: 19903804]

46. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al; New Technologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006;98:765-74. [PMID: 16757701]

47. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764-72. [PMID: 17919718]

48. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10:672-82. [PMID: 19540162]

49. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-97. [PMID: 17942872]

50. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009;101:88-99. [PMID: 19141778]

51. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ. 2010;340:c1804. [PMID: 20423964]

52. Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med. 2008;148:493-500. [PMID: 18378945]

53. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47:864-71. [PMID: 21334200]

54. McCaffery K, Waller J, Forrest S, Cadman L, Szarewski A, Wardle J. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG. 2004;111:1437-43. [PMID: 15663132]

55. Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P. The psychosocial impact of human papillomavirus testing in primary cervical screening-a study within a randomized trial. Int J Gynecol Cancer. 2008;18:743-8. [PMID: 17944916]

56. McCaffery KJ, Irwig L, Turner R, Chan SF, Macaskill P, Lewicka M, et al. Psychosocial outcomes of three triage methods for the management of borderline abnormal cervical smears: an open randomised trial. BMJ. 2010;340:b4491. [PMID: 20179125]

57. Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. BMJ. 2004;328:1293. [PMID: 15166066]

58. Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med. 2006;144:850-5. [PMID: 16754927]

59. Ogilvie GS, van Niekerk DJ, Krajden M, Martin RE, Ehlen TG, Ceballos K, et al. A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer. 2010;10:111. [PMID: 20334685]

60. Arbyn M, Rebolj M, De Kok IM, Fender M, Becker N, O'Reilly M, et al. The challenges of organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer. 2009;45:2671-8. [PMID: 19695867]

61. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103:368-83. [PMID: 21282563]

62. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al; Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754. [PMID: 18852164]

63. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46-52. [PMID: 12509400]

64. Kjaer S, Høgdall E, Frederiksen K, Munk C, van den Brule A, Svare E, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006;66:10630-6. [PMID: 17062559]

65. Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med. 2010;170:977-85. [PMID: 20548011]

66. Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol. 2010;134:193-9. [PMID: 20660320]

67. Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, et al; FUTURE I, II and III Investigators. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer. 2011;128:1354-62. [PMID: 20506504]

Return to Contents

Copyright and Source Information

Source: This article was first published in Annals of Internal Medicine (Ann Intern Med 2011 Oct 18. [Epub ahead of print]).

Acknowledgment: The authors thank Daphne Plaut, MLS, for conducting the literature searches; Kevin Lutz, MFA, for editorial support; and Rebecca Holmes, MD, MPH, and Sarah Zuber, MSW, for assistance in conducting the evidence review. They also thank the Agency for Healthcare Research and Quality and the USPSTF and Marc Arbyn, MD, MSc, DrTMH; Walter Kinney, MD; Mary Mitchell; Alan G. Waxman, MD, MPH; and Diana Petitti, MD, MPH, for their contribution to this evidence review.

Grant Support: By the Agency for Healthcare Research and Quality (contract HHS-290-2007-10057-I, task order 3).

Potential Conflicts of Interest: Drs. Whitlock, Vesco, Eder, and Lin and Ms. Senger: Grant (money to institution): Agency for Healthcare Research and Quality; Support for travel to meetings for the study or other purposes (money to institution): Agency for Healthcare Research and Quality; Payment for writing or reviewing the manuscript (money to institution): Agency for Healthcare Research and Quality. Drs. Whitlock, Eder, and Lin and Ms. Senger: Provision of writing assistance, medicines, equipment, or administrative support (money to institution): Agency for Healthcare Research and Quality. Ms. Senger: Support for travel to meetings for the study or other purposes (money to institution): National Institutes of Health. Ms. Burda: Grant (money to institution): Agency for Healthcare Research and Quality; Support for travel to meetings for the study or other purposes (money to institution): Agency for Healthcare Research and Quality; Consultancy: Oregon Health & Science University. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-1382 Exit Disclaimer.

Current author addresses: Drs. Whitlock, Vesco, Eder, Lin, and Ms. Senger and Ms. Burda: Center for Health Research, Kaiser Permanente Northwest, 3800 North Interstate Avenue, Portland, OR 97227.

AHRQ Publication No. 11-05156-EF-3
Current as of October 2011

Return to Contents


Internet Citation:

Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-Based Cytology and Human Papillomavirus Testing to Screen for Cervical Cancer: A Systematic Review for the U.S. Preventive Services Task Force. AHRQ Publication No. 11-05156-EF-3. October 2011. http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancerupd.htm


 


USPSTF Program Office   540 Gaither Road, Rockville, MD 20850